跳至主要内容
临床试验/EUCTR2009-009320-36-DK
EUCTR2009-009320-36-DK进行中(未招募)不适用

A Randomized, Double-Blind, 3-Arm Parallel-Group, 2-Year (104-Week), Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ 28431754 100 mg and JNJ-28431754 300 mg Compared With Glimepiride in the Treatment of Subjects With Type 2 Diabetes Mellitus Not Optimally Controlled on Metformin Monotherapy The CANTATA-SU Trial (CANagliflozin Treatment And Trial Analysis - Sulfonylurea) - The CANTATA-SU Trial (CANagliflozin Treatment And Trial Analysis-Sulfonylurea)

Janssen Cilag International NV0 个研究点目标入组 1,281 人开始时间: 2009年12月16日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
1,281

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Diagnosis of T2DM;
  • Taking a stable dosage of metformin at screening.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 897
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 384

排除标准

  • A history of diabetic ketoacidosis, type 1 diabetes mellitus, pancreas or beta-cell transplantation or diabetes secondary to pancreatitis or pancreatectomy;
  • History of one or more severe hypoglycaemic episodes within 6 months prior to screening.

研究者

相似试验

进行中(未招募)
1 期
A Randomized, Double-Blind, 3-Arm Parallel-Group, 2-Year (104-Week), Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ 28431754 100 mg and JNJ-28431754 300 mg Compared With Glimepiride in the Treatment of Subjects With Type 2 Diabetes Mellitus Not Optimally Controlled on Metformin Monotherapy The CANTATA-SU Trial (CANagliflozin Treatment And Trial Analysis - Sulfonylurea)MedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusType 2 Diabetes Mellitus
EUCTR2009-009320-36-NOJanssen Cilag International NV
进行中(未招募)
1 期
A Randomized, Double-Blind, 3-Arm Parallel-Group, 2-Year (104-Week), Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ 28431754 100 mg and JNJ-28431754 300 mg Compared With Glimepiride in the Treatment of Subjects With Type 2 Diabetes Mellitus Not Optimally Controlled on Metformin Monotherapy The CANTATA-SU Trial (CANagliflozin Treatment And Trial Analysis - Sulfonylurea)Type 2 Diabetes Mellitus
EUCTR2009-009320-36-SKJanssen Cilag International NV1,281
进行中(未招募)
不适用
The CANTATA-SU Trial (Canagliflozin Treatment And Trial Analysis-Sulfonylurea)Type 2 Diabetes Mellitus
EUCTR2009-009320-36-BGJanssen Cilag International NV1,281
进行中(未招募)
不适用
CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus GlimepirideMedDRA version: 14.0Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 2 Diabetes Mellitus
EUCTR2009-009320-36-FIJanssen Cilag International NV1,281
已完成
3 期
This study is to check the efficacy, safety, and tolerability of JNJ-28431754 compared with glimepiride in patients with type 2 diabetes
CTRI/2010/091/000595Johnson Johnson Pharmaceutical Research Development LLC1,281